Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Drug

Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis

Fineline Cube Dec 15, 2022

German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...

Drug

Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China

Fineline Cube Dec 15, 2022

Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...

Company Medical Device

Acotec Scientific’s NEO-Skater Balloon Approved by NMPA for Intracranial Vessels

Fineline Cube Dec 15, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approval from the National...

Company Drug

Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial

Fineline Cube Dec 15, 2022

China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...

Company Drug

Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC

Fineline Cube Dec 15, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...

Company Drug

Henlius Biotech Initiates Phase I Trial for HLX60 in Australia

Fineline Cube Dec 15, 2022

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...

Company Deals

China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China

Fineline Cube Dec 15, 2022

China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer...

Company Medical Device

Zylox-Tonbridge Receives NMPA Approval for ZYLOX Octoplus Vena Cava Filter

Fineline Cube Dec 15, 2022

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Innovent Biologics Collaborates with LG Chem for Tigulixostat in China

Fineline Cube Dec 15, 2022

China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...

Deals Drug

Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine

Fineline Cube Dec 15, 2022

China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...

Company Deals

Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics

Fineline Cube Dec 15, 2022

Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program

Fineline Cube Dec 14, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and...

Company Digital Drug

111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China

Fineline Cube Dec 14, 2022

China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...

Company Deals

Biosion and ImmunoGen Collaborate on Cancer ADCs

Fineline Cube Dec 14, 2022

China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...

Company Deals

Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics

Fineline Cube Dec 14, 2022

UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...

Company Deals

Henlius Biotech Partners with Medilink for Global ADC Development

Fineline Cube Dec 14, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...

Company Drug

Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study

Fineline Cube Dec 14, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...

Company Medical Device

Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study

Fineline Cube Dec 14, 2022

China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a...

Policy / Regulatory

China’s COVID-19 Vaccination Second Booster Shot Plan Released

Fineline Cube Dec 14, 2022

The National Health Commission website indicates that the COVID-19 Joint Prevention and Control Mechanism of...

Company Drug

ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval

Fineline Cube Dec 14, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...

Posts pagination

1 … 568 569 570 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.